David Hallal - Dec 20, 2021 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
Director
Signature
/s/ Adi Osovsky, as Attorney-in-Fact
Stock symbol
ITOS
Transactions as of
Dec 20, 2021
Transactions value $
-$2,004,000
Form type
4
Date filed
12/22/2021, 06:59 PM
Previous filing
Jun 22, 2021
Next filing
Jan 25, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITOS Common Stock Options Exercise $86K +20K $4.30 20K Dec 20, 2021 Direct
transaction ITOS Common Stock Options Exercise $88.5K +30K +150% $2.95* 50K Dec 20, 2021 Direct
transaction ITOS Common Stock Sale -$2.18M -50K -100% $43.57 0 Dec 20, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITOS Stock Option (Right to Buy) Options Exercise $0 -20K -14.85% $0.00 115K Dec 20, 2021 Common Stock 20K $4.30 Direct F2
transaction ITOS Stock Option (Right to Buy) Options Exercise $0 -30K -44.75% $0.00 37K Dec 20, 2021 Common Stock 30K $2.95 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.25 to $44.19, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2 One-fourth of the shares subject to the stock option vested on July 1, 2019. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date.
F3 One-fourth of the shares subject to the stock option vested on December 5, 2020. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date.